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Background: Renal sympathetic nerve activation contrib-
utes to the pathogenesis of hypertension. Symplicity HTN-2, a
multicenter, randomized trial, demonstrated that catheter-
based renal denervation produced significant blood pressure
lowering in treatment-resistant patients at 6 months after the
procedure compared with control, medication-only patients.
Longer-term follow-up, including 6-month crossover results,
is now presented.
Methods and results: Eligible patients were on 3 anti-
hypertensive drugs and had a baseline systolic blood pressure
160 mm Hg (150 mm Hg for type 2 diabetics). After the
6-month primary end point was met, renal denervation in
control patients was permitted. One-year results on patients
randomized to immediate renal denervation (n ¼ 47) and
6-month postprocedure results for crossover patients are
presented. At 12 months after the procedure, the mean fall in
office systolic blood pressure in the initial renal denervation
group (28.1 mm Hg; 95% confidence interval, 35.4 to 20.7;
p < 0.001) was similar to the 6-month fall (31.7 mm Hg; 95%
confidence interval, 38.3 to 25.0; p < 0.16 versus 6-month
change). The mean systolic blood pressure of the crossover
group 6 months after the procedure was significantly lowered
(from 190.0 19.6 to 166.3 24.7mmHg; change,23.7 27.5;
p < 0.001). In the crossover group, there was 1 renal artery
dissection during guide catheter insertion, before denerva-
tion, corrected by renal artery stenting, and 1 hypotensive
episode, which resolved with medication adjustment.Conclusions: Control patients who crossed over to renal
denervationwith the Symplicity systemhad a significant drop
in blood pressure similar to that observed in patients receiving
immediate denervation. Renal denervation provides safe and
sustained reduction of blood pressure to 1 year.
Clinical trial registration: URL: http://www.clinicaltrials.
gov. Unique identifier: http://www.clinicaltrials.gov. (Circu-
lation. 2012;126:2976e2982.)1. Clinical perspective
The efficacy and safety of the Renal sympathetic Denerva-
tion (RDN) by utilizing the Symplicity Renal Denervation
System in patients with uncontrolled resistant hypertension
have been documented earlier. It has been shown that
activation of the sympathetic nervous system is involved in
the pathogenesis and maintenance of hypertension. Renal
denervation with the Symplicity catheter is a minimally
invasive procedure based on the premise that interruption
of renal afferent and efferent nerves with resultant decrease
in sympathetic outflow to the kidneys should reduce renin
release and sodium retention, increase renal blood flow, and
lower blood pressure. One-year follow-up data of The Sym-
plicity HTN-2 trial demonstrates two points: (1) that the
initial significant lowering of blood pressure achieved by the
RDN procedure was maintained at the end of one year and
no procedure-related side effect was revealed by that time;
and (2) the control patients maintained on medical therapy
and whose blood pressure was not adequately controlled
were now permitted to switch over to RDN procedure. These
patients again showed significant drop in blood pressure,
which was maintained at the end of six months. Renal
sympathetic Denervation by radiofrequency ablation thus
may provide a safe and effective adjunctive therapy for
treatment-resistant hypertensive patients.
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